Table 1 Baseline characteristics of study patients per group
| Â | PPHG-miglitol | PPHG-control | NGT |
|---|---|---|---|
|  | n = 18 | n = 18 | n = 18 |
General characteristics | Â | Â | Â |
Age (years) | 60.6 ± 2.1 | 65.1 ± 2.2 | 60.3 ± 2.1 |
Sex, male, n (%) | 15 (83.3) | 14 (77.8) | 16 (88.9) |
Body mass index (kg/m2) | 25.1 ± 0.5 | 25.0 ± 0.7 | 25.3 ± 0.5 |
Hypertension, n (%) | 15 (83.3) | 16 (88.9) | 16 (88.9) |
Dyslipidemia, n (%) | 15 (83.3) | 14 (77.8) | 14 (77.8) |
Smoking, n (%) | 12 (66.6) | 11 (61.1) | 10 (55.6) |
Chronic kidney disease, n (%) | 4 (22.2) | 5 (27.8) | 7 (38.9) |
Laboratory values | Â | Â | Â |
Hemoglobin (mg/mL) | 13.6 ± 0.3 | 13.2 ± 0.2 | 13.1 ± 0.3 |
Creatinine (mg/mL) | 0.82 ± 0.04 | 0.85 ± 0.04 | 1.01 ± 0.06 |
eGFR (mL/min/1.73m2) | 69.5 ± 3.5 | 70.7 ± 2.6 | 63.1 ± 3.5 |
Hemoglobin A1c (%) | 6.4 ± 0.1* | 6.5 ± 0.1†| 5.6 ± 0.1 |
1,5-AG (μg/mL) | 11.4 ± 1.1** | 11.5 ± 1.0††| 20.8 ± 1.8 |
Glycated albumin (%) | 15.4 ± 0.4* | 15.2 ± 0.5†| 14.2 ± 0.3 |
HOMA-IR | 2.69 ± 0.38* | 2.22 ± 0.47†| 1.69 ± 0.17 |
Total cholesterol (mg/dL) | 196.0 ± 12.2 | 195.5 ± 8.2 | 202.1 ± 7.1 |
HDL cholesterol (mg/dL) | 45.8 ± 2.1 | 47.0 ± 2.1 | 46.0 ± 2.5 |
LDL cholesterol (mg/dL) | 126.6 ± 12.0 | 125.3 ± 7.6 | 136.3 ± 5.7 |
Creatine phospho-kinase (max) (IU/L) | 2360.6 ± 465.2 | 2453.3 ± 487.6 | 3174.7 ± 626.2 |
NT-proBNP (pg/mL) | 666.3 ± 280.5 | 664.9 ± 238.6 | 616.7 ± 279.9 |
Medications being used | Â | Â | Â |
Calcium channel blockers, n (%) | 4 (22.2) | 8 (44.4) | 6 (33.3) |
Beta blockers, n (%) | 12 (66.7) | 8 (44.4) | 18 (44.4) |
ACE-Is or ARBs, n (%) | 13 (72.2) | 12 (66.7) | 12 (66.7) |
Nitrates, n (%) | 11 (61.1)** | 12 (66.7)††| 18 (100) |
Statins, n (%) | 15 (83.3) | 14 (77.8) | 14 (77.8) |